Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer

A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01069796

Enrollment

Registered

2010-02-17

Start date

2010-04-30

Completion date

2014-06-30

Last updated

2016-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Triple Negative Metastatic Breast Cancer

Keywords

triple negative, metastatic, breast cancer, First line chemotherapy

Brief summary

Patients with triple negative metastatic breast cancer (HER2-, PR-, ER-) will receive bevacizumab, paclitaxel and capecitabine as a first line of treatment (possibility to have received adjuvant chemotherapy).

Interventions

DRUGPaclitaxel

80 mg/m² weekly

DRUGBevacizumab

10 mg/kg d1 d15

DRUGCapecitabine

800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 & 3

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Female histologically confirmed adenocarcinoma of the breast ER-, PR-, HER2- disease * Measurable disease * Patients may received prior radiotherapy as adjuvant treatment or/and metastatic disease provided that they have progressive disease at study entry

Exclusion criteria

* Prior chemotherapy for metastatic disease * HER2 positive and/or hormonal receptor positive

Design outcomes

Primary

Measure	Time frame
objective response rate	36 months for recrutment and 30 months for follow up

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026